Tango Therapeutics, Inc.
Clinical trials sponsored by Tango Therapeutics, Inc., explained in plain language.
-
New combo targets Hard-to-Treat cancers with STK11 mutation
Disease control Recruiting nowThis study is for adults with advanced solid tumors that have a specific genetic change called STK11 mutation. The goal is to test a new drug, TNG260, given alone or with an immunotherapy drug (pembrolizumab). Researchers want to find the best dose, check safety, and see if the c…
Phase: PHASE1, PHASE2 • Sponsor: Tango Therapeutics, Inc. • Aim: Disease control
Last updated May 15, 2026 11:56 UTC
-
New pill targets cancers with missing gene in early trial
Disease control Recruiting nowThis study tests a new oral drug, TNG462, in people with advanced solid tumors that lack the MTAP gene. The goal is to find a safe dose and see if it can shrink tumors, alone or with another drug. Up to 225 adults with specific tumor types will take part in this early-phase trial…
Phase: PHASE1, PHASE2 • Sponsor: Tango Therapeutics, Inc. • Aim: Disease control
Last updated May 15, 2026 11:54 UTC